Daval International awarded orphan drug designation for ALS

The US FDA has granted UK’s Daval International Ltd’s drug, AIMSPRO, an Orphan Drug Designation for ALS. AIMSPRO, a derivate of hyperimmune caprine serum, is currently in Phase II trials in Europe for scleroderma and for bladder dysfunction in Secondary Progressive Multiple Sclerosis. AIMSPRO’s veterinary counterpart has already shown safety and efficacy in horses.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail